A detailed history of Candriam S.C.A. transactions in Natera, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 306,615 shares of NTRA stock, worth $52.4 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
306,615
Previous 200,007 53.3%
Holding current value
$52.4 Million
Previous $21.7 Million 79.93%
% of portfolio
0.23%
Previous 0.13%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$97.75 - $129.67 $10.4 Million - $13.8 Million
106,608 Added 53.3%
306,615 $39 Million
Q2 2024

Aug 05, 2024

SELL
$85.28 - $112.6 $2.39 Million - $3.15 Million
-28,001 Reduced 12.28%
200,007 $21.7 Million
Q1 2024

May 03, 2024

SELL
$59.21 - $92.9 $827,696 - $1.3 Million
-13,979 Reduced 5.78%
228,008 $20.9 Million
Q4 2023

Feb 14, 2024

SELL
$37.55 - $62.64 $1.8 Million - $3.01 Million
-48,003 Reduced 16.55%
241,987 $15.2 Million
Q3 2023

Nov 13, 2023

SELL
$43.4 - $62.52 $652,041 - $939,300
-15,024 Reduced 4.93%
289,990 $12.8 Million
Q2 2023

Aug 08, 2023

BUY
$47.08 - $55.16 $8.51 Million - $9.98 Million
180,851 Added 145.66%
305,014 $14.8 Million
Q1 2023

May 12, 2023

BUY
$36.57 - $58.29 $2.53 Million - $4.03 Million
69,163 Added 125.75%
124,163 $6.89 Million
Q4 2022

Feb 13, 2023

BUY
$34.17 - $47.91 $341,700 - $479,099
10,000 Added 22.22%
55,000 $2.21 Million
Q3 2022

Nov 10, 2022

BUY
$36.93 - $56.68 $1.66 Million - $2.55 Million
45,000 New
45,000 $1.97 Million
Q1 2022

May 13, 2022

SELL
$30.32 - $91.33 $290,223 - $874,210
-9,572 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$86.26 - $119.0 $65,298 - $90,083
757 Added 8.59%
9,572 $894,000
Q3 2021

Nov 09, 2021

BUY
$100.17 - $126.36 $882,998 - $1.11 Million
8,815 New
8,815 $982,000

Others Institutions Holding NTRA

About Natera, Inc.


  • Ticker NTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 96,957,400
  • Market Cap $16.6B
  • Description
  • Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...
More about NTRA
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.